Industrial Market Strategy for 2026: Fierce Competition, Comprehensive Bull Market Sets Sail

Since the beginning of this year, the three major logics have continued to consolidate, and a virtuous cycle between the capital market and the real economy has been established, solidifying the underlying logic of this bull market.

1 h ago

Original YuanChuang Group (001325.SZ) IPO price set at 24.75 yuan per share, subscription to start on December 9th. Improved YuanChuang Group (001325.SZ) sets IPO price at 24.75 yuan per share, subscription to begin on December 9th.

Yuan Chuang shares (001325.SZ) announced that the company has determined the issue price for this issuance to be 24.75 yuan per share. Investors are requested to subscribe at this price on December 9, 2025 (T day) through the Shenzhen Stock Exchange trading system and apply for subscription using the online market value subscription method, without the need to pay for the subscription funds. The online subscription date is December 9, 2025 (T day), and the online subscription time is 9:15-11:30, 13:00-15:00.

1 h ago

China National Chemical Engineering (601117.SH): Nylon new material project reaches production.

China Chemical (601117.SH) announced that its third-tier holding subsidiary, Tianchen Qixiang New Materials Co., Ltd., has successfully implemented a non-public offering investment project for the nylon new materials project. In the 72-hour full-load performance assessment conducted recently, the key technologies and economic indicators of the adiponitrile plant have all met or exceeded the design values. The product quality is stable and controllable, and the system operates smoothly and efficiently. Currently, it has achieved full production and entered a phase of efficient and stable operation.

1 h ago

HAITONG INT'L: As the policy window approaches, the market rebound momentum is expected to continue.

This week, the market fluctuated with lower trading volume. Next week, driven by the expectation of policies heating up, it is expected to continue the rebound trend. However, the strength of the rebound still depends on the intensity of policy implementation and whether the Federal Reserve will cut interest rates.

2 h ago

INNOGEN-B (02591) core product included in the "National Medical Insurance Drug List"

Yinuo Medicine-B (02591) announced that the group's core product (ie. Ipragliflozin) has been successfully included in the latest version of China's National Reimbursement Drug List (2025 Edition) for the treatment of type 2 diabetes ("T2D") indications. The latest version of the National Reimbursement Drug List will officially take effect on January 1, 2026.

3 h ago

DL HOLDINGS GP (01709) intends to subscribe for 19,047,600 shares of YTME.

Trin Holdings (01709) announced that on December 5, 2025 (after trading hours), the company entered into a subscription agreement with YTME, pursuant to which (i) the company conditionally agreed to subscribe, and YTME conditionally agreed to issue and allot, a total of 19.0476 million YTME subscription shares at the subscription price of 0.42 Swiss francs per share (equivalent to approximately HK$4.10) for a total consideration of $10 million, of which part will be paid in cash and part will be paid by issuing and allotting shares to YTME at a price to be determined by the company after completion.

3 h ago

GENSCRIPT BIO(01548): Legend announces report published at the 2025 ASH Annual Meeting.

Kingsway Biotech (01548) issued an announcement that Legend Biotech Corporation ("Legend"), a joint venture company of the Company, whose shares are listed on the Nasdaq Global Select Market in the United States in the form of American Depositary Shares, announced on December 6, 2025 (New York time) that CARVYKTI (cilta-cel) had been presented in a verbal report at the 2025 American Society of Hematology ("ASH") Annual Meeting providing the long-term follow-up clinical and translational research data from the CARTITUDE-1 and CARTITUDE-4 studies in patients with relapsed or refractory multiple myeloma (RRMM).

4 h ago

On December 5th, MNSO (09896) spent $248,400 to repurchase 51,300 shares.

MINISO (09896) announced that on December 5, 2025, the company spent $248,400 to repurchase 51,300 shares.

4 h ago

Cui Dongshu: The internal turmoil of the automobile market has significantly weakened, and the industry's operating pressure has improved.

In 2025, promotions and downgrading in the automotive industry both return to rationality, and the market order significantly improves.

4 h ago

TAIZHOU WATER (01542) plans to invest 200 million yuan to participate in the establishment of a fund, fulfilling the responsibilities of state-owned enterprises and focusing on the upgrading of the automotive and medical health industries.

Taizhou Water Affairs (01542) announced that the board of directors has proposed to establish a fund with Taizhou Jin Tou Chuang Yue, Shanghai Yicun, Taizhou Jin Tou Equity Investment, Taizhou State-owned Asset Investment, and Taizhou Kai Tou, by entering into a fund partnership agreement with an initial proposed size of RMB 1.01 billion. The company's proposed capital contribution is RMB 200 million, accounting for approximately 19.8% of the total committed capital of the fund.

4 h ago

TAIZHOU WATER (01542) plans to increase its capital by 300 million yuan to support the upgrading of water infrastructure.

Taizhou Water Affairs (01542) announced that Binhai Water Affairs was established on June 7, 2016 with a registered capital of 300 million RMB. As of the date of this announcement, it is a subsidiary of the company, with 51% owned by the company and 49% owned by Taizhou Urban Water Affairs. As of the date of this announcement, Binhai Water Affairs has a paid-up capital of 300 million RMB. It mainly engages in the financing, construction, and operation management of Taizhou City's water diversion project, which started supplying water in October 2022.

4 h ago

TAIZHOU WATER (01542) suggests issuing debt financing instruments through non-public targeted issuance.

Taizhou Water Affairs (01542) announced that, in order to optimize the company's capital structure, reduce financial expenses, and further enhance the overall strength of the company, it issued debt financing instruments through a non-publicly targeted issuance at a special resolution passed by shareholders at the company's special general meeting on December 23, 2022. In June 2023, the non-publicly targeted debt financing instruments issued in 2022 were approved by the China Foreign Exchange Trading System Brokers Association (with a registered amount not exceeding RMB 1 billion). As of the date of this announcement, the Group has issued a total of three tranches (each tranche amounting to RMB 150 million) of non-publicly targeted debt financing instruments, with one tranche of debt financing instruments due on January 7, 2026 still outstanding.

4 h ago

TAIZHOU WATER (01542) suggests electing Yang Feng as a non-executive director.

Taizhou Water Affairs (01542) has issued an announcement recommending the election of Mr. Yang Feng as a non-executive director. His term will begin on the date approved by shareholders at the special general meeting until the end of the term of the sixth board of directors. If his appointment is approved by shareholders at the special general meeting, he will become a member of the nomination committee.

4 h ago

CG SERVICES (06098): Tian Tian has been appointed as Chief Financial Officer.

Country Garden Services (06098) announced that Mr. Huang Peng has resigned as the Chief Financial Officer of the company, effective from December 5, 2025, in order to devote more time and effort to managing the group's incubation business.

4 h ago

Vice President Yu Ze of PICC Group (01339) is suspected of serious violations of discipline and law and is currently undergoing disciplinary review and supervision investigation by the Central Commission for Discipline Inspection and the National Supervisory Commission.

China People's Insurance Group (01339) announced that, according to the information disclosed on the website of the Central Commission for Discipline Inspection and the National Supervisory Commission on December 6, 2025, Yu Ze, Vice President of China People's Insurance Group Co., Ltd., is suspected of serious disciplinary violations and illegal activities and is currently undergoing disciplinary review and supervision investigation by the Central Commission for Discipline Inspection and the National Supervisory Commission. This matter does not affect the company's business operations.

4 h ago

YUM CHINA (09987) spent 19.19 million Hong Kong dollars on December 5 to repurchase 53,200 shares.

Parkson China (09987) announced that on December 5, 2025, the company repurchased 53,200 shares at a cost of HK$19.19 million.

4 h ago

LUYE PHARMA(02186) successfully included five new products in the 2025 National Medical Insurance Drug Catalog or Commercial Insurance Innovative Drug Catalog.

Green Leaf Pharmaceutical (02186) announced that a total of five new products from the group have been successfully included in the "National Essential Medicine Insurance, Maternity Insurance and Work Injury Insurance Drug List (2025)" (National Medical Insurance Drug List) or the "Commercial Health Insurance Innovation Drug List (2025)" (Commercial Health Insurance Innovation Drug List) released by the National Medical Security Administration.

4 h ago

Jiangsu Hengrui Pharmaceuticals' products included in the national medical insurance directory.

Hengrui Medicine (01276) announced that, according to the notice issued by the National Medical Insurance Bureau and the Ministry of Human Resources and Social Security on the publication of the "National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalogue (2025)" ("National Medical Insurance Catalogue" for short), some products of Jiangsu Hengrui Medicine Co., Ltd. (referred to as "Hengrui Medicine" or "the Company") have been included in the National Medical Insurance Catalogue.

4 h ago

HENLIUS (02696): Futoxing (Citric Acid Phenyl Ethyl Alcohol Capsule) has been included in the National Medical Insurance Drug List.

Fuhong Hanlin (02696) announced that recently, Fulunin (fulvestrant capsules) has been included in the Category B range of the "National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug List (2025)", with the indication for use in combination with fluorouracil for hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative recurrent or metastatic adult breast cancer patients who have experienced disease progression after previous hormonal therapy. The new version of the national medical insurance drug list will be officially implemented starting January 1, 2026.

4 h ago

AKEOS (09926)5 drugs that have been marketed have all successfully been included in the latest version of the national medical insurance drug list.

Kangfang Bio (09926) announced that all indications for Kangfang Bio's five newly launched drugs, including Cankenit (ciddutinib, PD-1/CTLA-4), Ivofax (Ivosci, PD-1/VEGF), Annicay (Piantipri, PD-1), Inisitin (Inusci, PCSK9) and Eidaro (Irokimni, IL-12/IL-23), have successfully been included in the latest version of the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2025)" published by the China National Medical Insurance Administration.

4 h ago

GMT Eight

GMT Eight